Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion evaluating mechanistic and preclinical literature.
PubMed 33161784 · doi:10.1080/14737175.2021.1847645
What was done
The authors conducted a narrative review synthesizing literature on the neuroprotective potential of metformin in central and peripheral nervous system disorders. The review focused on metformin's mechanism of action—specifically AMP-activated protein kinase (AMPK) activation, downstream mammalian target of rapamycin (mTOR) pathway suppression, mitochondrial refurbishment, and autophagy induction—in conditions such as Parkinson's disease, Huntington's disease, peripheral neuropathy, and neuropathic pain. The therapeutic actions of metformin were also compared with resveratrol.
What was found
The abstract reports no quantitative data, effect sizes, or study counts. It qualitatively summarizes that metformin-driven AMPK activation and autophagy enhancement can improve neuronal bioenergetics, promote nerve repair, and decrease toxic protein aggregates in preclinical models of neurological disorders.
Why it matters
Metformin is an established, widely available drug with an extensive clinical safety profile in type 2 diabetes. Repurposing it as an AMPK activator could offer a viable strategy to target underlying metabolic deficits and proteostasis failure in neurodegenerative and neuropathic conditions.
Limits
This is a narrative review presenting expert opinion without a systematic search protocol or quantitative meta-analysis. The abstract provides no specific outcome metrics or clinical trial data, relying primarily on mechanistic and preclinical animal models that have not yet translated to confirmed human neurotherapeutic efficacy.
Cited by
- supports The diabetes drug metformin acts to stimulate AMP kinase.